Y NSGKLEEFVR GNLERECIEE
KCSFEEAREV FENTEKTTEF WKQYVDGDQC ESNPCLNDGV CKDDINSYEC WCRAGFEGKN
CELDVTCNIK NGRCKQFCKL GPDNKVVCSC TTGYQLAEDQ RSCEPAVPFP CGRVSVPHIS
MTRTRAETLF SNMDYENSTE VEKILDNVTQ PLNDFTRVVG GKDAKPGQFP WQVLLNGKVD
AFCGGSIINE KWVVTAAHCI EPDVKITIVA GEHNTEKREH TEQKRNVIRT ILHHSYNATI
NKYNHDIALL ELDEPLTLNS YVTPICIADR EYSNIFLKFG SGYVSGWGRV FNKGRSASIL
QYLKVPLVDR ATCLRSTKFT IYNNMFCAGF HEGGKDSCQG DSGGPHVTEV EGISFLTGII
SWGEECAMKG KYGIYTKVSR YVNWIKEKTK LT Note: The complete
sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is
translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application,
please explicitly request the full and complete sequence of this protein before ordering.
Protein Length
Full Length of Mature Protein
Tag Info
N-terminal His-tagged/Tag-Free The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Storage
Store at -20°C, for extended storage, conserve at -20°C or -80°C.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.
Gene References into Functions
Report relative sensitivity of whole blood clotting time and activated partial thromboplastin time for the detection of factor IX.PMID:22482117
Data indicate that the hyperactivating factor IX (FIX)-R338L mutation resulted in a robust 15-fold gain in potency and therefore provides a promising strategy to improve the efficacy, feasibility, and safety of hemophilia gene therapy.PMID:23043073
Data indicate that factor IX (FIX)-R338L provides an attractive strategy to safely enhance the efficacy of gene therapy for hemophilia B (HB).PMID:22919027
Describe proliferation of FIX-producing dog hepatocytes in mouse liver.PMID:18449417